Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed

5 days ago · Get Our Latest Research Report on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Stock Down 2.8 %. Shares of NASDAQ RARE traded down $1.41 during …

CouponFollow Extension

$1.41
OFF

Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed

1 week from now

5 days ago · Get Our Latest Research Report on Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical Stock Down 2.8 %. Shares of NASDAQ RARE traded down $1.41 during …

marketbeat.com

$111.00
OFF

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns "Overweight" …

1 week from now

Oct 22, 2024 · Canaccord Genuity Group reaffirmed a "buy" rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. The …

marketbeat.com

$129.00
OFF

Jefferies Keeps Their Buy Rating On Ultragenyx Pharmaceutical …

1 week from now

Oct 7, 2024 · In a report released today, Maury Raycroft from Jefferies maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $129.00.The …

businessinsider.com

$121
OFF

RARE Stock Price | Ultragenyx Pharmaceutical Inc. Stock Quote …

1 week from now

3 days ago · Stifel Nicolaus Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE) Nov. 6, 2024 at 7:57 a.m. ET on TipRanks.com Ultragenyx price target raised to $121 from …

marketwatch.com

$47.76
OFF

Ultragenyx Pharmaceutical Inc (RARE) Stock Price & News - Google

1 week from now

The range between the high and low prices over the past day. $47.76 - $49.37. Year range. The range between the high and low prices over the past 52 weeks. $36.51 - $60.37. Market cap. …

google.com

$81.00
OFF

Barclays Sticks To Its Buy Rating For Ultragenyx Pharmaceutical …

1 week from now

Oct. 1, 2024, 01:46 AM. In a report released today, Gena Wang from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $81.00. …

businessinsider.com

FAQs about Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reaffirmed Coupon?

Should you buy Ultragenyx Pharmaceutical (rare – research report)?

In a report released today, Gena Wang from Barclays maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a price target of $81.00. The company’s shares closed yesterday at $55.55. According to TipRanks, Wang is a 4-star analyst with an average return of 7.6% and a 43.69% success rate. ...

Who owns Ultragenyx Pharmaceutical Inc?

Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA. RARE | Complete Ultragenyx Pharmaceutical Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Should you buy Raycroft & Ultragenyx Pharmaceutical?

According to TipRanks, Raycroft has an average return of 7.4% and a 40.08% success rate on recommended stocks. Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $87.56, which is a 62.78% upside from current levels. ...

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical is a company that develops therapeutics for rare diseases, sometimes referred to as Orphan products. Effective and efficient development strategies are essential for success in the rare disease space, where information may be incomplete or ambiguous, and few development precedents exist. Ultragenyx Pharmaceutical's management team ...

How did Ultragenyx Pharmaceutical perform compared to last year?

Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $147.03 million and a GAAP net loss of $131.6 million. In comparison, last year the company earned a revenue of $108.31 million and had a GAAP net loss of $159.83 million ...

Why did Whitney Ijem buy Ultragenyx Pharmaceutical?

Whitney Ijem has given his Buy rating due to a combination of factors pertaining to Ultragenyx Pharmaceutical’s promising gene therapy treatments. The updated long-term follow-up data from Phase 1/2 studies of DTX401 and DTX301 therapies have shown consistent results with previous updates, displaying significant potential for treatment efficacy. ...